Biotechnology Acquisitions in 2022
Acquisition Volume in Biotechnology in 2022 by Year
Last 5 years
-
December 21, 2022
- Buyer
- Vistagen
- Target
- Pherin Pharmaceuticals, Inc.
- Seller
- Pherin Pharmaceuticals' stockholders
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.
-
December 14, 2022
- Buyer
- Kite (a Gilead Company), Gilead Sciences, Inc.
- Target
- Arcellx, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Growth capital
Kite, a Gilead company, will make a $225 million upfront cash payment plus a $100 million equity investment in Arcellx to co-develop and co-commercialise Arcellx's lead CAR-T candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma. The companies will share development and U.S. commercial economics (50/50 U.S. profits for co-commercialised products), with Kite responsible for manufacturing after technical transfer; ex-U.S. commercialization will be led by Kite with royalties to Arcellx.
-
December 8, 2022
- Buyer
- Arsenal Capital Partners
- Target
- Certara, Inc.
- Seller
- Funds controlled by EQT Private Equity
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Growth capital
Arsenal Capital Partners closed a previously announced $449 million stock purchase in Certara, acquiring shares from funds controlled by EQT Private Equity and becoming a long-term minority investor. As part of the transaction Arsenal appointed Operating Partner David Spaight to Certara's board while Stephen McLean remains a director; Arsenal agreed to a two-year lock-up on the newly purchased shares.
-
December 6, 2022
- Buyer
- Molecular Devices, LLC
- Target
- Cellesce Ltd
- Industry
- Biotechnology
- Location
- Wales, United Kingdom
- Type
- Buyout
Molecular Devices, a life-science instrumentation company, has acquired Cellesce Ltd, a Cardiff-based developer and manufacturer of patient-derived organoids (PDOs) for large-scale drug screening. The deal expands Molecular Devices' 3D biology capabilities and combines Cellesce's industrial-scale PDO production with Molecular Devices' automated organoid screening platforms to accelerate adoption of physiologically relevant cell models in drug discovery.
-
November 29, 2022
- Buyer
- AstraZeneca
- Target
- Neogene Therapeutics
- Seller
- Vida Ventures, TPG, EcoR1 Capital, Jeito Capital, Syncona, Polaris Partners, Pontifax, Two River Advisors, Arie Belldegrun
- Industry
- Biotechnology
- Location
- Netherlands
- Type
- Buyout
AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.
-
November 28, 2022
- Buyer
- Bionano Genomics, Inc.
- Target
- Purigen Biosystems, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Bionano Genomics agreed to acquire Purigen Biosystems to integrate Purigen's isotachophoresis (ITP) Ionic Purification System into Bionano's optical genome mapping (OGM) workflow, aiming to simplify ultra-high molecular weight (UHMW) DNA isolation and address difficult sample types. The deal consideration is up to $64 million (including $32 million cash at closing and milestone-contingent payments) and was expected to close by December 8, 2022.
-
November 28, 2022
- Buyer
- Full‑Life Technologies
- Target
- Focus‑X Therapeutics
- Seller
- Focus‑X Therapeutics shareholders, Viva Biotech (portfolio investor)
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Full‑Life Technologies, a global radiotherapeutics company, agreed to acquire New Jersey‑based Focus‑X Therapeutics to expand its peptide‑focused radiopharmaceutical pipeline. Focus‑X shareholders are eligible for an upfront payment plus up to $245 million in development, regulatory and sales milestones and royalties; the deal was expected to close in Q1 2023.
-
November 23, 2022
- Buyer
- Biocare Medical, GHO Capital Partners LLP
- Target
- Empire Genomics
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Addon
Biocare Medical, a GHO Capital-backed provider of automated IHC and FISH instrumentation and reagents, has acquired Empire Genomics, a designer and manufacturer of FISH/CISH probes and molecular biomarkers. The deal expands Biocare's molecular portfolio (bringing over one million biomarkers) and adds rapid biomarker development capabilities to accelerate cancer research and diagnostics.
-
November 21, 2022
- Buyer
- Merck
- Target
- Imago BioSciences, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Merck (MSD) entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Imago BioSciences in an all-cash deal valued at approximately $1.35 billion (=$36.00 per share). Merck will commence a tender offer for all outstanding shares, with the transaction expected to close in the first quarter of 2023, subject to customary conditions.
-
November 16, 2022
- Buyer
- Kriya Therapeutics, Inc.
- Target
- Redpin Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Kriya Therapeutics has acquired Redpin Therapeutics, a preclinical New York City–based gene therapy company with a proprietary chemogenetics platform. The deal establishes Kriya's neurology therapeutic-area portfolio by adding Redpin’s lead programs targeting epilepsy and trigeminal neuralgia, and brings chemogenetic capability to Kriya’s gene therapy engine.
-
November 16, 2022
- Buyer
- Alexion, AstraZeneca Rare Disease
- Target
- LogicBio Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Alexion, AstraZeneca Rare Disease completed its acquisition of LogicBio Therapeutics, a Lexington, Massachusetts-based genomic medicine company. The deal was implemented through a cash tender offer and a merger of an Alexion subsidiary with LogicBio, with LogicBio becoming a wholly owned subsidiary of Alexion.
-
November 9, 2022
- Buyer
- Angus Chemical Company
- Target
- Expression Systems, LLC
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Addon
Angus Chemical Company (a PE-backed specialty ingredients manufacturer) has acquired Expression Systems, LLC, a Davis, California-based maker of cell culture media, baculovirus reagents, cell lines and related contract services. The acquisition expands Angus' life‑sciences capabilities into specialty cell culture media and strengthens its bioprocessing product and service offering; Achelous Partners served as exclusive advisor to Expression Systems.
-
November 8, 2022
- Buyer
- Leica Biosystems
- Target
- Cell IDx
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Leica Biosystems has acquired Cell IDx, a San Diego-based leader in multiplexed tissue profiling, integrating Cell IDx's UltraPlex multiplex IHC technology with Leica's BOND RX automation to expand translational research and multiplexing capabilities. The deal advances Leica's research-focused staining and imaging portfolio and brings scale-up and medical/scientific affairs support for Cell IDx customers.
-
November 7, 2022
- Buyer
- Fulgent Genetics, Inc.
- Target
- Fulgent Pharma Holdings, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.
-
- Buyer
- Ignyte Acquisition Corp., Peak Bio, Inc. (formerly Peak Bio Co., Ltd. after combination)
- Target
- Peak Bio Co., Ltd.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Ignyte Acquisition Corp. completed its business combination with clinical-stage biopharmaceutical company Peak Bio Co., Ltd. The combined company began trading on NASDAQ as “Peak Bio, Inc.” under ticker “PKBO.” The transaction followed stockholder approvals at Ignyte’s special meeting on October 25, 2022.
-
November 1, 2022
- Buyer
- Avista Capital Partners
- Target
- Taconic Biosciences
- Seller
- H.I.G. Capital
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Avista Capital Partners has acquired Taconic Biosciences from H.I.G. Capital. Taconic, a Rensselaer, New York–based provider of genetically engineered murine research models and related preclinical services, will leverage Avista's healthcare investing expertise to pursue organic growth and strategic acquisitions in the GEMs market.
-
October 31, 2022
- Buyer
- NuChem Sciences, Fonds de solidarité FTQ
- Target
- IniXium
- Industry
- Biotechnology
- Location
- Québec, Canada
- Type
- Buyout
Montreal-based contract research organization NuChem Sciences has acquired IniXium of Laval, Québec, with investment support from the Fonds de solidarité FTQ. The deal expands NuChem's structural biology and recombinant protein production capabilities—integrating IniXium's crystallography and fragment screening expertise into NuChem's drug-discovery services.
-
October 26, 2022
- Buyer
- Mana Capital Acquisition Corp.
- Target
- Cardio Diagnostics, Inc., Cardio Diagnostics Holdings, Inc.
- Seller
- Meeshanthini (Meesha) Dogan (representative of Cardio shareholders)
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Mana Capital Acquisition Corp. completed its business combination with Cardio Diagnostics, resulting in Cardio Diagnostics Holdings, Inc. being listed on Nasdaq under ticker CDIO (common stock) and CDIOW (warrants). The deal had been supported by a previously announced definitive merger agreement dated May 27, 2022 and required multiple extensions to complete before closing.
-
October 24, 2022
- Buyer
- Beckley Psytech Limited
- Target
- Eleusis Therapeutics Limited
- Industry
- Biotechnology
- Location
- England, United Kingdom
- Type
- Buyout
Beckley Psytech Limited has acquired 100% of Eleusis Therapeutics Limited in an all-equity transaction, adding Eleusis' clinical-stage assets (including ELE-101) and its R&D team to Beckley's pipeline. Eleusis CEO Shlomi Raz will join Beckley as Chief Business Officer as the companies integrate to accelerate development of short-duration psychedelic therapies.
-
October 24, 2022
- Buyer
- Avista Public Acquisition Corp. II (APAC), Avista Capital Partners
- Target
- OmniAb, Inc.
- Seller
- Ligand Pharmaceuticals Incorporated
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Ligand Pharmaceuticals has signed a definitive merger agreement to spin off its OmniAb antibody discovery business into a newly formed standalone public company, OmniAb, Inc., via a Reverse Morris Trust. OmniAb will then merge with Avista Public Acquisition Corp. II (APAC), backed by Avista Capital Partners, with the combined company expected to be renamed OmniAb, Inc. and listed on Nasdaq.
-
October 23, 2022
- Buyer
- Syncona Limited
- Target
- Applied Genetic Technologies Corporation
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Syncona Limited will acquire Applied Genetic Technologies Corporation (AGTC) via a tender offer, paying $0.34 per share in cash upfront (approximately $23.5 million) with contingent value rights (CVRs) that could provide up to an additional $0.73 per share (up to $50.0 million) for total potential consideration of up to $1.07 per share. The transaction, unanimously approved by AGTC’s board, will take AGTC private and is intended to advance AGTC's retinal gene therapy programs amid funding challenges for the public company.
-
October 18, 2022
- Buyer
- Eli Lilly and Company
- Target
- Akouos, Inc.
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Eli Lilly and Company signed a definitive agreement to acquire Akouos, a precision genetic medicine company focused on adeno-associated viral (AAV) gene therapies for inner ear conditions including sensorineural hearing loss. The transaction is valued at approximately $487 million upfront, plus a contingent value right (CVR) of up to $610 million in aggregate, and is expected to close in Q4 2022 subject to customary conditions.
-
October 11, 2022
- Buyer
- Pasithea Therapeutics Corp.
- Target
- AlloMek Therapeutics, LLC
- Industry
- Biotechnology
- Location
- Connecticut, United States
- Type
- Buyout
Pasithea Therapeutics Corp. (Nasdaq: KTTA) acquired AlloMek Therapeutics, LLC, obtaining the preclinical MEK 1/2 inhibitor CIP-137401 to expand its CNS-focused drug-development pipeline. The deal closed on October 11, 2022 and included $1.05 million in upfront cash, issuance of restricted stock and warrants, plus potential clinical/regulatory milestones and royalties.
-
October 7, 2022
- Buyer
- ARCHIMED, MED Platform II (ARCHIMED fund)
- Target
- PlasmidFactory
- Industry
- Biotechnology
- Location
- North Rhine-Westphalia, Germany
- Type
- Buyout
Transatlantic healthcare private equity firm ARCHIMED (via its MED Platform II fund) has invested in PlasmidFactory, a Bielefeld, Germany-based contract manufacturer of plasmid and minicircle DNA used in gene and cell therapies. The founder and management will remain in place with a roll-over of a portion of proceeds; proceeds will fund rapid expansion including construction of a larger GMP-compliant production facility to meet growing demand.
-
October 4, 2022
- Buyer
- Eurobio Scientific
- Target
- GenDx (Genome Diagnostics B.V.)
- Seller
- Erik Rozemuller, Wietse Mulder, Other GenDx shareholders (including minority investor Ampersand Capital Partners)
- Industry
- Biotechnology
- Location
- Utrecht, Netherlands
- Type
- Buyout
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
- Buyer
- Pfizer Inc.
- Target
- Biohaven Pharmaceutical Holding Company Ltd., Biohaven Ltd.
- Industry
- Biotechnology
- Location
- Connecticut, United States
- Type
- Buyout
Pfizer completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant). The all-cash transaction is valued at approximately $11.6 billion and makes Biohaven a wholly owned subsidiary of Pfizer.
-
September 29, 2022
- Buyer
- Great Point Partners
- Target
- iXCells Biotechnologies
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Growth capital
Great Point Partners, a Greenwich, CT-based healthcare-focused private investment firm, has made a growth investment in San Diego-based iXCells Biotechnologies. The capital will be used to expand iXCells' operational capacity, broaden its product and service offering (including bioanalytical capabilities) and support growth into adjacent high-growth end markets such as personalized medicine and rare disease research.
-
September 28, 2022
- Buyer
- GENinCode plc
- Target
- Abcodia Limited
- Industry
- Biotechnology
- Location
- Cambridgeshire, United Kingdom
- Type
- Buyout
Oxford-based GENinCode plc has acquired Cambridge-based Abcodia Limited and its Risk of Ovarian Cancer Algorithm (ROCA) test on an earnout basis with a maximum consideration of £1 million. The acquisition marks GENinCode’s first entry into oncology as it plans to accelerate ROCA revenues in the UK and pursue market entry in the United States and European Union.
-
September 28, 2022
- Buyer
- Idera Pharmaceuticals, Inc.
- Target
- Aceragen, Inc.
- Seller
- NovaQuest Co-Investment Fund XV, L.P. / NovaQuest Capital Management LLC
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Idera Pharmaceuticals completed an all-stock acquisition of Aceragen, a privately held biotech focused on rare pulmonary and rheumatic diseases, adding Aceragen's lead programs ACG-701 and ACG-801 to Idera's pipeline. The transaction was structured as a stock-for-stock exchange, includes management appointments from Aceragen, and is expected to provide pro forma cash runway into Q3 2023 while advancing Aceragen's clinical milestones.
-
September 21, 2022
- Buyer
- Sesen Bio, Inc., Carisma Therapeutics Inc.
- Target
- Sesen Bio, Inc., Carisma Therapeutics Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Sesen Bio, Inc. and Carisma Therapeutics Inc. have entered into a definitive merger agreement in an all-stock transaction to combine their businesses and create a well-funded, clinical-stage biotechnology company focused on engineered macrophage cell therapies for cancer and other serious disorders. The combined company is expected to trade on Nasdaq as Carisma Therapeutics Inc. under the ticker “CARM” and have approximately $180 million in cash at close, including $30 million from a concurrent financing by Carisma.
-
September 20, 2022
- Buyer
- Rocket Pharmaceuticals, Inc.
- Target
- Renovacor, Inc.
- Industry
- Biotechnology
- Location
- Connecticut, United States
- Type
- Buyout
Rocket Pharmaceuticals (NASDAQ: RCKT) will acquire Renovacor (NYSE: RCOR) in an all-stock transaction valued at approximately $53 million (implied $2.60 per Renovacor share). The acquisition strengthens Rocket's leadership in AAV-based cardiac gene therapy by adding Renovacor's REN-001 BAG3-targeted program and related capabilities to Rocket's clinical pipeline.
-
September 20, 2022
- Buyer
- Gilead Sciences, Inc.
- Target
- MiroBio Ltd
- Industry
- Biotechnology
- Location
- Oxfordshire, United Kingdom
- Type
- Buyout
Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.
-
September 16, 2022
- Buyer
- Delwinds Insurance Acquisition Corp.
- Target
- FOXO Technologies Inc.
- Industry
- Biotechnology
- Location
- Minnesota, United States
- Type
- Buyout
FOXO Technologies Inc., a longevity-focused epigenetics and AI platform for the life insurance industry, completed a business combination with SPAC Delwinds Insurance Acquisition Corp., resulting in FOXO listing on the NYSE American under the ticker FOXO. The transaction positions FOXO to commercialize its molecular biomarkers and saliva-based underwriting protocols and to scale its FOXO Longevity Report and MGA distribution relationships.
-
- Buyer
- Syros Pharmaceuticals, Inc.
- Target
- Tyme Technologies, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Syros Pharmaceuticals (NASDAQ: SYRS) closed its merger with Tyme Technologies, acquiring TYME’s pipeline assets and net cash at closing. The transaction included a concurrent oversubscribed $130 million private investment in public equity (PIPE), and the combined company trades on Nasdaq under the SYRS ticker.
-
September 13, 2022
- Buyer
- Beckman Coulter Life Sciences (part of Danaher Corporation)
- Target
- ValitaCell Ltd.
- Industry
- Biotechnology
- Location
- Ireland
- Type
- Buyout
Beckman Coulter Life Sciences, a Danaher company, has acquired Dublin-based ValitaCell Ltd., a developer of analytical products and technologies for the biopharmaceutical industry. The acquisition adds ValitaCell’s ValitaTiter and related cell-analytics products to Beckman Coulter’s portfolio to accelerate biologics development and manufacturing workflows.
-
September 12, 2022
- Buyer
- BioIVT
- Target
- XenoTech
- Seller
- Sekisui Chemical
- Industry
- Biotechnology
- Location
- Kansas, United States
- Type
- Divestiture
BioIVT has acquired XenoTech, a Kansas City–based provider of ADME‑Tox in vitro models and contract research services, from Sekisui Chemical. The acquisition expands BioIVT's hepatic product portfolio and ADME/DMPK capabilities to better support biopharma customers' preclinical testing needs. Financial terms were not disclosed.
-
September 7, 2022
- Buyer
- Roche
- Target
- Good Therapeutics
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Roche has entered into a definitive merger agreement to acquire Good Therapeutics, a Seattle-based privately held biopharmaceutical company, for an upfront $250 million plus milestone payments. The deal gives Roche rights to Good Therapeutics' conditionally active PD-1-regulated IL-2 program and an exclusive right to the platform for developing PD-1-regulated IL-2 receptor agonists; the transaction is expected to close in Q3 2022 subject to HSR clearance.
-
September 7, 2022
- Buyer
- Arcutis Biotherapeutics, Inc.
- Target
- Ducentis BioTherapeutics Ltd.
- Industry
- Biotechnology
- Location
- United Kingdom
- Type
- Buyout
Arcutis Biotherapeutics (Nasdaq: ARQT) has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical biotechnology company developing the CD200R agonist DS-234 for atopic dermatitis. The deal includes approximately $16 million in cash and roughly $14 million in Arcutis stock up front, plus contingent development-and-commercial milestones, and is intended to accelerate Arcutis' biologics pipeline and strengthen its dermatology capabilities.
-
September 5, 2022
- Buyer
- GBA Group
- Target
- KaLy-Cell SAS
- Industry
- Biotechnology
- Location
- Grand Est, France
- Type
- Addon
GBA Group has acquired French contract research organization KaLy-Cell SAS, marking the group's market entry into France and expanding its European pharmaceutical network. KaLy-Cell, founded in 2003 as a spin-off from the University of Bourgogne Franche-Comté and headquartered in Plobsheim, provides hepatocyte-based in vitro contract research and safety testing services for pharmaceuticals, agrochemicals and cosmetics.
-
August 30, 2022
- Buyer
- Ampersand Capital Partners, Dr. Glenn Haifer
- Target
- Luina Bio (rebranded AcuraBio)
- Industry
- Biotechnology
- Location
- Queensland, Australia
- Type
- Buyout
Biotech investor Dr. Glenn Haifer and healthcare private equity firm Ampersand Capital Partners have acquired Australian CDMO Luina Bio and rebranded it as AcuraBio. The investors plan to inject capital to expand production capacity, broaden service offerings and build AcuraBio into a leading APAC biologics contract development and manufacturing organization.
-
August 30, 2022
- Buyer
- Novo Holdings A/S, LeapFrog Investments, Sofina
- Target
- MedGenome
- Industry
- Biotechnology
- Location
- Karnataka, India
- Type
- Growth capital
Novo Holdings led a $50 million minority investment in MedGenome alongside existing investors LeapFrog Investments and Sofina. The capital will support MedGenome’s expansion beyond South Asia into Africa and the Middle East and broaden access to its genomic testing, bioinformatics and research services.
-
August 16, 2022
- Buyer
- GSK plc
- Target
- Affinivax, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.
-
- Buyer
- SFW Capital Partners
- Target
- Sannova Analytical, Inc.
- Seller
- Marepalli family, Dr. Venkat Reddy, Malleswar Kollu, Geeta Vidiyala, Founders and existing owners
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Growth capital
SFW Capital Partners completed a strategic growth investment in Sannova Analytical, a Somerset, New Jersey-based bioanalytical CRO that provides bioanalytical and CMC testing services to pharmaceutical and biotech companies. Founders and existing owners (including the Marepalli family, Dr. Venkat Reddy, Malleswar Kollu, and Geeta Vidiyala) are reinvesting and retaining an equity stake; SFW will support expansion of services, capacity, and pursue strategic acquisitions to accelerate growth.
-
August 10, 2022
- Buyer
- OceanTech Acquisitions I Corp.
- Target
- Captura Biopharma, Inc.
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
OceanTech Acquisitions I Corp., a special purpose acquisition company, signed a definitive merger agreement with Captura Biopharma to take the biotech company public. The combined company is expected to operate under the name Captura Biopharma Holdings, Inc. and remain listed on Nasdaq, subject to SEC, regulatory, and stockholder approvals.
-
- Buyer
- Pfizer Inc.
- Target
- Global Blood Therapeutics, Inc. (GBT)
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Pfizer entered into a definitive agreement to acquire Global Blood Therapeutics (GBT), paying $68.50 per share in cash for an enterprise value of about $5.4 billion. The deal adds GBT’s sickle cell disease portfolio, including Oxbryta (voxelotor), along with clinical pipeline assets such as GBT021601 (GBT601) and inclacumab.
-
August 4, 2022
- Buyer
- Amgen
- Target
- ChemoCentryx
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Amgen agreed to acquire ChemoCentryx for $52 per share in cash (approximately $3.7 billion enterprise value), gaining TAVNEOS (avacopan), a first-in-class oral therapy for ANCA-associated vasculitis. The deal, unanimously approved by both boards, is intended to strengthen Amgen's inflammation and nephrology portfolio and is expected to close following stockholder and regulatory approvals.
-
July 28, 2022
- Buyer
- Keensight Capital, Axxam management
- Target
- Axxam
- Seller
- Bayer SpA, Zambon Company SpA
- Industry
- Biotechnology
- Location
- Lombardy, Italy
- Type
- Buyout
Keensight Capital has agreed to acquire a majority stake in Axxam, an Italian innovative partner research organization (iPRO) headquartered in Milan, investing alongside Axxam's management. The sellers include current shareholders such as Bayer SpA and Zambon Company SpA; Axxam employs around 180 people and reported roughly €30 million of sales in 2021. Keensight intends to support the management team to accelerate growth and further develop Axxam's discovery capabilities.
-
July 25, 2022
- Buyer
- Ginkgo Bioworks (Ginkgo Bioworks, Inc.)
- Target
- Zymergen
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.
-
- Buyer
- Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Company N.V. (newly formed holding company)
- Target
- NewAmsterdam Pharma Holding B.V., NewAmsterdam Pharma Company N.V. (newly formed holding company)
- Industry
- Biotechnology
- Location
- Netherlands
- Type
- Buyout
Frazier Lifesciences Acquisition Corporation (FLAC) has entered into a definitive business combination agreement with NewAmsterdam Pharma Holding B.V. to create a publicly listed company, NewAmsterdam Pharma Company N.V., focused on transformative oral therapies for major cardiometabolic diseases. The transaction includes an upsized PIPE of approximately $235 million led by Frazier Healthcare Partners and Bain Capital Life Sciences and is expected to close in the second half of 2022, subject to customary conditions and FLAC shareholder approval.
-
- Buyer
- Lygos, Inc., Flexible Solutions International, Inc. (FSI)
- Target
- Lygos, Inc., Flexible Solutions International, Inc. (FSI)
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Lygos, Inc. and Flexible Solutions International, Inc. (FSI) announced they have entered into a definitive, all-stock merger agreement to form a leading sustainable specialty ingredient company. The companies plan to integrate their complementary technology platforms and expand production and the portfolio of multi-functional organic acids, with the transaction expected to close in the third quarter of 2022 subject to approvals and customary conditions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.